Antihistamines Should NOT Be Routinely Used for Vertigo
Clinicians should not routinely treat vertigo with antihistamines or benzodiazepines, as these medications lack evidence for effectiveness in the most common cause of vertigo (BPPV) and may increase fall risk. 1, 2
The Evidence Against Routine Antihistamine Use
The American Academy of Otolaryngology—Head and Neck Surgery guidelines explicitly recommend against routine use of vestibular suppressant medications (antihistamines and benzodiazepines) for benign paroxysmal positional vertigo (BPPV), which is the most common vestibular disorder in adults 1, 2. This recommendation is based on:
- No evidence that antihistamines work as definitive treatment for BPPV or as substitutes for repositioning maneuvers
- Studies showing resolution with medications simply followed patients through the natural spontaneous resolution period (mean 39 days) 1
- Significant harm potential: A 2025 study found meclizine use was associated with nearly 3-fold increased risk of injurious falls in patients aged 18-64 years (HR 2.94) and 2.5-fold increased risk in those ≥65 years (HR 2.54) 3
When Antihistamines May Be Considered (Limited Exceptions)
Short-term symptom relief only:
Antihistamines may be used only for short-term management of severe nausea/vomiting in acutely symptomatic patients who refuse other treatments 1, 2. Common agents mentioned include:
- Meclizine
- Diphenhydramine
However, a 2022 meta-analysis found that while single-dose antihistamines provided modest vertigo relief at 2 hours compared to benzodiazepines, daily antihistamine use showed no benefit for acute vertigo at 1 week or 1 month 4.
Specific vestibular conditions (not BPPV):
For Ménière's disease specifically, antihistamines are listed as a treatment option in the 2020 guidelines, with betahistine (a histamine analogue) noted to increase vasodilation to the inner ear 5. Studies show betahistine 48 mg/day can be effective for peripheral vertigo from various causes 6, 7, though this medication is not FDA-approved in the United States.
Critical Safety Concerns
Fall risk is substantial:
- First-generation antihistamines cause sedation, impaired balance, and anticholinergic effects (dry mouth, constipation, urinary retention, narrow-angle glaucoma risk) 8
- Older adults are particularly vulnerable to psychomotor impairment, falls, fractures, and subdural hematomas 8
- Performance impairment persists into the next day even when dosed at bedtime due to prolonged half-lives 8
Antihistamines interfere with diagnosis:
Vestibular suppression from antihistamines decreases diagnostic sensitivity during Dix-Hallpike maneuvers 1, 2
The Correct Treatment Approach
For BPPV (most common cause):
- Particle repositioning maneuvers (Epley maneuver) are the primary treatment—up to 4.1 times more effective than observation 1
- Vestibular rehabilitation may be offered as adjuvant therapy, especially for residual dizziness or balance issues 2
- Observation is acceptable if patient prefers, with reassessment within 1 month 1
For other peripheral vertigo causes:
- Identify the specific etiology (Ménière's disease, vestibular neuritis, etc.)
- Treat the underlying condition appropriately
- Consider betahistine for Ménière's disease if available 5
Bottom Line Algorithm
- Diagnose the type of vertigo (BPPV vs. other causes)
- For BPPV: Use repositioning maneuvers, NOT medications
- For severe nausea/vomiting only: Consider single-dose antihistamine (diphenhydramine 25-50 mg or meclizine) while arranging definitive treatment
- Never use antihistamines as primary or ongoing treatment for vertigo
- Avoid entirely in older adults due to fall risk unless absolutely necessary for intractable symptoms
The evidence is clear: antihistamines are guideline-discordant care for the most common cause of vertigo and carry significant morbidity risk through increased falls 3.